Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Public ClinicalTrials.gov record NCT01690520. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Study identification
- NCT ID
- NCT01690520
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Nohla Therapeutics, Inc.
- Industry
- Enrollment
- 163 participants
Conditions and interventions
Conditions
Interventions
- Cyclophosphamide Drug
- Cyclosporine Drug
- Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion Biological
- Fludarabine Phosphate Drug
- Mycophenolate Mofetil Drug
- Thiotepa Drug
- Total-Body Irradiation Radiation
- Umbilical Cord Blood Transplantation Procedure
Drug · Biological · Radiation + 1 more
Eligibility (public fields only)
- Age range
- 6 Months to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2012
- Primary completion
- Sep 17, 2018
- Completion
- May 28, 2020
- Last update posted
- Jul 5, 2021
2012 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Stanford Cancer Institute Palo Alto | Palo Alto | California | 94304 | — |
| University of Colorado | Denver | Colorado | 80217-3364 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01690520, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01690520 live on ClinicalTrials.gov.